36.38
0.38 (1.06%)
| Previous Close | 36.00 |
| Open | 36.14 |
| Volume | 219,670 |
| Avg. Volume (3M) | 1,501,892 |
| Market Cap | 3,509,853,952 |
| Price / Sales | 3.52 |
| Price / Book | 239.96 |
| 52 Weeks Range | |
| Earnings Date | 4 Nov 2025 |
| Profit Margin | -93.04% |
| Operating Margin (TTM) | -102.62% |
| Diluted EPS (TTM) | -5.83 |
| Quarterly Revenue Growth (YOY) | 28.00% |
| Total Debt/Equity (MRQ) | 588.24% |
| Current Ratio (MRQ) | 2.40 |
| Operating Cash Flow (TTM) | -389.94 M |
| Levered Free Cash Flow (TTM) | -172.94 M |
| Return on Assets (TTM) | -24.51% |
| Return on Equity (TTM) | -377.06% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Biotechnology (US) | Bullish | Mixed |
| Biotechnology (Global) | Bullish | Mixed | |
| Stock | Ultragenyx Pharmaceutical Inc. | Bearish | Bearish |
AIStockmoo Score
| Analyst Consensus | 3.0 |
| Insider Activity | NA |
| Price Volatility | -2.0 |
| Technical Moving Averages | -2.5 |
| Technical Oscillators | -2.5 |
| Average | -1.00 |
|
Ultragenyx Pharmaceutical Inc is a USA-based biopharmaceutical company. It identifies, acquires, develops, and commercializes novel products for the treatment of serious rare and ultra-rare diseases, with a focus on serious, debilitating genetic diseases. The company's medicine portfolio includes Crysvita, Dojolvi and Mepsevii. Crysvita is indicated for the treatment of X-linked hypophosphatemia (XLH) in adult and pediatric patients 1 year of age and older. Mepsevii is indicated in pediatric and adult patients for the treatment of Mucopolysaccharidosis VII. |
|
| Sector | Healthcare |
| Industry | Biotechnology |
| Investment Style | Small Core |
| % Held by Insiders | 3.20% |
| % Held by Institutions | 99.43% |
| 52 Weeks Range | ||
| Price Target Range | ||
| High | 90.00 (Truist Securities, 147.39%) | Buy |
| Median | 60.50 (66.30%) | |
| Low | 45.00 (Wells Fargo, 23.69%) | Buy |
| Average | 62.25 (71.11%) | |
| Total | 8 Buy | |
| Avg. Price @ Call | 26.24 | |
| Firm | Date | Target Price | Call | Price @ Call |
|---|---|---|---|---|
| B of A Securities | 02 Jan 2026 | 58.00 (59.43%) | Buy | 22.28 |
| Baird | 30 Dec 2025 | 47.00 (29.19%) | Buy | 22.78 |
| Jefferies | 30 Dec 2025 | 63.00 (73.17%) | Buy | 22.78 |
| Leerink Partners | 30 Dec 2025 | 70.00 (92.41%) | Buy | 22.78 |
| Wells Fargo | 30 Dec 2025 | 45.00 (23.69%) | Buy | 22.78 |
| Barclays | 24 Nov 2025 | 50.00 (37.44%) | Buy | 32.78 |
| TD Cowen | 05 Nov 2025 | 75.00 (106.16%) | Buy | 31.87 |
| Truist Securities | 05 Nov 2025 | 90.00 (147.39%) | Buy | 31.87 |
No data within this time range.
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2026 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |